SCHEMBL334644

SCHEMBL334644

CCN(CCCC(=O)O)C(C)c1ccccc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
BCHE P06276 4/20 0.43
ACHE P22303 4/20 0.43
POLB P06746 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYSLTR2 Q9NS75 2/20 0.39
CYSLTR1 Q9Y271 2/20 0.39
PGR P06401 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334643 1.00 LMNA (0.44) LMNABCHEACHEPOLBHTT
SCHEMBL334443 0.96 BCHE (0.47) LMNABCHEACHEPOLBHTT
SCHEMBL335831 0.95 ACHE (0.49) LMNABCHEACHEPOLBHTT
SCHEMBL10243139 0.88 PPARG (0.46) BCHEACHEPOLBHTTNPSR1
SCHEMBL10245591 0.86 ACHE (0.41) BCHEACHENPSR1L3MBTL1SMN1; SMN2
SCHEMBL10243410 0.85 HPGD (0.41) BCHEACHEHTTNPSR1L3MBTL1
SCHEMBL10243108 0.85 PPARG (0.47) BCHEACHE
SCHEMBL10243344 0.84 PPARG (0.49) BCHEACHE
SCHEMBL10282710 0.84 APP (0.43) LMNAPOLBHTTNPSR1L3MBTL1
SCHEMBL10243135 0.81 APP (0.43) BCHEACHEPOLBL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 LMNA 1467/4885BCHE 1393/4885ACHE 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.